|
I.S. Vladimirova
Psoriasis, metabolic syndrome and COVID-19: a case report
|
№14 / 2022
|
|
D.V. Nebieridze, N.M. Akhmedzhanov, A.S. Safaryan
Current management strategy for high-risk hypertensive patients – focus on lipid-lowering therapy
|
№9 / 2019
|
|
N.P. Lyamina, E.S. Karpova
CARDIOVASCULAR SAFETY AND EFFICACY OF CELECOXIB: FOCUS ON TREATMENT AND CARDIOSOMATIC REHABILITATION
|
№15 / 2017
|
|
Z.M. Safiullina, L.A. Salnikova, S.V. Shalaev
DURATION OF DUAL ANTIPLATELET THERAPY: DEBATABLE QUESTIONS AND POSSIBLE SOLUTIONS
|
№9 / 2016
|
|
S.V. Shalaev (1, 2), Z.M. Safiullina (1), N.A. Mikhalchuk (1)
STATINS AND THE RISK FOR NEW-ONSET DIABETES: RISK-BENEFIT RATIO. MODERN VIWES ON TARGET LIPID LEVELS IN DIABETES PATIENTS
|
№16 / 2014
|
|
A.P. Rebrov, E.V. Grigorieva
MODERN ANTIHYPERTENSIVE THERAPY: FOCUS ON LERCANIDIPINE
|
№10 / 2014
|
|
N.V. Chichasova
THE USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND RISK OF CARDIOVASCULAR COMPLICATIONS
|
№9 / 2014
|
|
L.A. Strizhakov, S.V.Moiseev, E.N. Semenkova, E.A. Cogan, S.P. Pasha, E.I. Kuznetsova, V.E. Ditterle, N.A. Mukhin
CLINICAL PATHOMORPHOLOGICAL VERSIONS OF HEART DISEASE IN PATIENTS WITH SYSTEMIC VASCULITIS AND FEATURES OF NON-INVASIVE DIAGNOSTIC METHODS
|
№9 / 2013
|
|
E.V. Biryukova
Rational Choice Of Pharmacotherapy In Type 2 Diabetes Mellitus
|
№5 / 2013
|
|
Shishkova V.N.
Current Approaches To Therapy Type 2 Diabetes – Effect On Insulin Resistance
|
№3 / 2011
|
|
Birukova E.V.
How To Achieve Effective Glycemic Control And Reduce The Risk Of Vascular Complications Due To Using Sulfonylurea Medications
|
№3 / 2011
|
|
V.V. Fomin, V.V. Panasyuk
Features Of Management Of Elderly Patients With Acute Myocardial Infarction
|
№13 / 2010
|
Русский
